Binet Staging System for Chronic Lymphocytic Leukemia (CLL)

Stage alone should not dictate treatment; consider symptoms and patient comorbidities. Use clinical judgment and specialist recommendations to guide management decisions.

• Low risk (stage A):
  • Monitor with a "watch and wait" approach unless symptoms or disease progression occurs.
  • Focus on regular follow-ups and patient education.
• Intermediate risk (stage B):
  • A “watch and wait” approach may be appropriate for asymptomatic individuals.
  • Assess for additional prognostic factors and signs of disease progression.
  • Consider initiating treatment if symptomatic or if there is rapid progression.
• High risk (stage C):
  • Initiate appropriate therapy based on patient and tumor characteristics, as well as goals of care.
  • Evaluate for clinical trials, especially in cases of high-risk genetic mutations.
• For early-stage, asymptomatic CLL (stages A and B), consider the IPS-E to predict the time to first treatment, helping to reaffirm treatment decisions and guide monitoring frequency.